# Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma

> **NCT02391662** · PHASE2 · COMPLETED · sponsor: **Asociación de Oncología Médica del Hospital de Cruces** · enrollment: 80 (actual)

## Conditions studied

- Pancreatic Carcinoma Metastatic

## Interventions

- **DRUG:** Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4
- **DRUG:** Gemcitabine 1000 weeks 1,2,3/4

## Key facts

- **NCT ID:** NCT02391662
- **Lead sponsor:** Asociación de Oncología Médica del Hospital de Cruces
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-23
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02391662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02391662, "Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02391662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*